FDA approved Tecvayli (teclistamab-cqyv), a Johnson & Johnson drug developed for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one of line of ...
Market access strategies are evolving as more biopharma companies commercialize their own therapies, requiring closer ...
Series C proceeds position Spectris for pivotal top-line data, regulatory submission, and launch planning ahead of a targeted ...
While regulatory alignment remains essential, operational urgency driving companies to AI adoption is equally profound. In ...
Employer Connect aggregates diverse administrators, from basic benefits management to comprehensive obesity programs with wraparound services, enabling employers to tailor coverage models to workforce ...
A $400 million, four-year Blackstone Life Sciences financing supports ongoing and future duvakitug development, with ...
In today’s Pharmaceutical Executive Daily, Cognito Therapeutics and Nexcure secure new financing rounds to advance their pipelines, artificial intelligence and large language models reshape ...
In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older ...
Bavarian Nordic CEO Paul Chaplin will step down by the end of 2026 after overseeing the company’s transformation into a ...
In this Pharmaceutical Executive Academy discussion, Najat Khan, PhD, CEO of Recursion Pharmaceuticals and former chief data ...
PE: What is the reaction to DTC pharma advertising? Donaldson: Consumers will slowly but surely have increased distrust in ...
Boehringer Ingelheim acquires an exclusive license for a preclinical oral immunology program from Sitryx in a deal worth over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results